Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround

Teva Pharmaceutical (TEVA) has surged 110% over the past year, reaching a 52-week high of $40.79 per share as the company executes a strategic pivot from generic to branded drugs. The shift centers on three branded products projected to generate $3.7 billion in revenue by 2026, marking a fundamental transformation in the company's business model.

The turnaround extends to Teva's balance sheet. Net debt dropped from $18.4 billion at the end of 2022 to $12.9 billion, triggering a credit rating upgrade to investment-grade status. This deleveraging comes as the company's late-stage pipeline promises peak annual sales of $10 billion.

Analysts see the rally as justified by fundamentals. Earnings growth of 40.7% is expected between 2026 and 2027, while the stock trades at 12.9 times forward earnings—a valuation analysts consider undervalued given the growth trajectory and pipeline potential.

The combination of debt reduction, pipeline maturation, and the branded-drug transition represents a multi-year restructuring now reflected in both the stock price and credit profile.